Olive Polyphenols (Hydroxytyrosol)

This page as PDF · Summary

1. What Olive Polyphenols Are

Hydroxytyrosol is a phenolic alcohol from the group of olive polyphenols, naturally occurring in olive leaves, fruits, and extra virgin olive oil. Chemically, it belongs to the secoiridoids, a subgroup of phenolic acids, and is formed through the hydrolysis of the bitter glucoside oleuropein. It is water-soluble and exhibits high antioxidant capacity, often compared in vitro to that of vitamin E. In addition to hydroxytyrosol, olive products contain other structurally related compounds such as tyrosol, oleocanthal, and oleacein, which are collectively responsible for the biological effects.

Critical to the study landscape is the diversity of formulations: research examines extra virgin olive oil, extracts from leaves or pomace, isolated hydroxytyrosol, or enriched dietary supplements. Bioavailability varies significantly depending on the matrix—fat-soluble forms (e.g., in oil) exhibit different absorption patterns compared to aqueous extracts. Furthermore, hydroxytyrosol is rapidly metabolised in the body, so sulphate and glucuronide conjugates are often measured in blood instead of the parent compound. Most studies therefore assess metabolites rather than the original substance, complicating the interpretation of dose-response relationships. Another key issue: the polyphenol profiles of olive products depend heavily on cultivar, cultivation, processing, and storage, making direct comparisons between studies often impossible.

2. What the Studies Show in Detail

Key human studies and major reviews — by application area, including population, duration, preparation, measured parameters, and results, as reported in the original publications. Numbers are included only where the study provides them.

Distribution of controlled human studies by application area — numbers are not additive, as a single study may be assigned to multiple areas:

Inflammatory Processes

In a randomised, double-blind, placebo-controlled crossover study involving 46 overweight men (mean age 46.4 ± 5.5 years, BMI 28.0 ± 2.0 kg/m²), a daily olive leaf extract containing 51.1 mg oleuropein and 9.7 mg hydroxytyrosol was administered over 12 weeks. The primary endpoint was insulin sensitivity (Matsuda method), with secondary endpoints including glucose and insulin profiles, cytokines, lipid profile, body composition, 24-hour blood pressure, and carotid intima-media thickness. Administration of the extract led to a significant 15% improvement in insulin sensitivity (p = 0.024) and a 28% increase in pancreatic β-cell reactivity (p = 0.013) compared to placebo. Additionally, fasting levels of the pro-inflammatory cytokine interleukin-6 (IL-6) rose significantly (p = 0.014), suggesting complex immunomodulatory effects. Limitations include the short 12-week intervention period, which precludes conclusions about long-term effects, and the lack of differentiation between the effects of oleuropein and hydroxytyrosol 1.

An acute, randomised, double-blind, placebo-controlled crossover study with 18 healthy participants (9 men, 9 women) investigated the effect of an olive leaf extract (51 mg oleuropein, 10 mg hydroxytyrosol) on vascular function and inflammatory markers. Vascular stiffness (measured via digital volume pulse, DVP) and ex vivo production of the pro-inflammatory cytokine IL-8 following LPS stimulation decreased significantly (p < 0.05) compared to placebo. The effects correlated with the urinary excretion of hydroxytyrosol and oleuropein metabolites, which peaked at 8–24 hours. The small sample size and absence of a dose-response analysis limit generalisability 6.

In a randomised, controlled crossover study involving 10 healthy participants and 10 patients with chronic kidney disease (K-DOQI stages III–IV), the influence of white wine (4 ml/kg body weight, 0.48 g/kg alcohol) combined with extra virgin olive oil (2–3 glasses/day) on inflammatory markers was examined. After a two-week intervention, a reduction in systemic inflammatory markers was observed. The study suggests potential synergistic effects of polyphenols in the combination, but it does not isolate the contribution of hydroxytyrosol or other individual compounds. The short duration and small sample size limit the study’s validity.

A randomised, controlled study involving 91 participants (33 men, 58 women) with obesity (BMI 30–40 kg/m²) and prediabetes investigated the effect of extra virgin olive oil (EVOO) with high oleocanthal and oleacein content compared to regular olive oil (OO) over one month. The primary endpoint was inflammatory status, with secondary endpoints including oxidative stress, body weight, glucose metabolism, and lipid profile. Following EVOO intake, interferon-γ levels decreased significantly (p = 0.041), while antioxidant capacity increased and lipid peroxides declined. The study showed effects of the olive polyphenol mixture, though data on long-term effects and the specific role of hydroxytyrosol are lacking 14.

Hypothesis The studies suggest that olive polyphenols such as hydroxytyrosol and oleuropein exert anti-inflammatory effects through multiple mechanisms, including modulation of cytokines (IL-6, IL-8, IFN-γ) and improvement of endothelial function. However, effects vary depending on dose, preparation (extract vs. native oil), and population, complicating standardised assessment. It remains unclear whether the observed effects are primarily due to antioxidant or specific anti-inflammatory properties.

Large-scale, multicentre long-term studies with clearly defined dose-response relationships and differentiation of individual polyphenols remain to be conducted to validate the clinical relevance for chronic inflammatory conditions.

Absorption and Bioavailability

In a randomised study involving nine participants (5 men, 4 women; mean age 42.8 ± 7.4 years), the bioavailability and metabolism of oleuropein and hydroxytyrosol following intake of an olive leaf extract (OLE) were investigated. Participants received either capsules or liquid extract in two dosages (low: 51.1 mg oleuropein, 9.7 mg hydroxytyrosol; high: 76.6 mg oleuropein, 14.5 mg hydroxytyrosol). Primary metabolites in plasma and urine were conjugated forms of hydroxytyrosol (sulphated and glucuronidated). The maximum plasma concentration of oleuropein was significantly higher after liquid extract intake (2.74 vs. 0.47 ng/ml, p = 0.004), while the peak concentration of conjugated hydroxytyrosol was independent of preparation form (p = 0.94). Time to maximum concentration of hydroxytyrosol was shorter with liquid intake (64 vs. 93 minutes, p = 0.031). Sex-specific differences in bioavailability were observed but not quantified further 2.

A randomised, controlled study involving 20 participants examined the pharmacokinetics and bioavailability of hydroxytyrosol (5 mg) in different food matrices (extra virgin olive oil, refined olive oil, flaxseed oil, grapeseed oil). The maximum plasma concentration of hydroxytyrosol was significantly higher 30 minutes after intake of extra virgin olive oil (3.79 ng/ml) compared to other matrices. Urinary excretion of hydroxytyrosol and its metabolites (hydroxytyrosol acetate, DOPAC, tyrosol, homovanillyl alcohol) was highest after intake of extra virgin olive oil (0.86 µg/mg creatinine) and enriched refined olive oil (0.63 µg/mg creatinine). The study shows that the bioavailability of hydroxytyrosol strongly depends on the food matrix, with native oils enhancing absorption. However, the short 12-hour observation period limits conclusions about long-term metabolism 8.

Hypothesis The bioavailability of hydroxytyrosol is influenced not only by dose but also by preparation form (liquid vs. capsule) and food matrix (e.g., native vs. refined oil). Native oils appear to optimise absorption, potentially through synergistic effects with other oil components such as fatty acids. It remains unclear whether these differences have clinically relevant impacts on anti-inflammatory or antioxidant effects.

Systematic studies on the bioavailability of olive polyphenols in complex meals and long-term data on accumulation and metabolism in different populations (e.g., elderly patients, patients with malabsorption) are lacking.

Metabolism

In a double-blind, randomised, parallel-group study involving 40 patients with stage-1 hypertension, the effect of an olive leaf extract (500 mg twice daily, standardised to oleuropein) was compared to captopril (initial dose 12.5 mg twice daily, titrated to 25 mg) over 8 weeks. The primary endpoint was reduction in systolic blood pressure (SBP). Both groups showed a significant reduction in SBP (extract: -11.5 ± 8.5 mmHg; captopril: -13.7 ± 7.6 mmHg; p < 0.01 vs. baseline), with no significant differences between groups. Secondary endpoints such as diastolic blood pressure (DBP) and lipid profile (triglycerides, LDL cholesterol) also improved in both groups. The study showed an antihypertensive effect of the extract, though data on long-term effects and the specific role of individual components such as hydroxytyrosol within the complex are lacking 4.

A randomised, double-blind crossover study involving 33 participants with cardiovascular risk investigated the endogenous conversion of tyrosol to hydroxytyrosol and its effects on cardiovascular biomarkers. Participants received white wine (1–2 standard glasses/day), white wine plus tyrosol capsules (25 mg tyrosol per glass), or water across three intervention phases. The combination of white wine and tyrosol led to significantly higher urinary excretion of hydroxytyrosol (p < 0.05) and showed potential effects on endothelial function, HDL cholesterol, homocysteine, and inflammatory markers (IL-6, CD40L) in humans. The short duration and lack of a placebo control for tyrosol alone limit the study’s validity 9.

In a randomised, double-blind study involving 16 healthy participants, the effect of yoghurt enriched with olive polyphenols (50 mg polyphenols/400 g yoghurt) was investigated over two weeks. Primary endpoints were body composition, blood parameters, and oxidative stress. Regardless of intervention, body weight, BMI, and hip circumference decreased significantly (p < 0.05). In the polyphenol arm, there was a trend towards reduced LDL cholesterol (p = 0.06) and thiobarbituric acid-reactive substances (p < 0.05). The study suggests metabolic effects of olive polyphenols, though data on the specific effects of individual polyphenols and long-term effects are lacking.

Hypothesis Olive polyphenols such as oleuropein and hydroxytyrosol influence metabolism through multiple pathways, including improvement of endothelial function, reduction of blood pressure and lipids, and modulation of inflammatory markers. The endogenous conversion of tyrosol to hydroxytyrosol may represent an additional mechanism that enhances cardioprotective effects. It remains unclear whether these effects are dose-dependent and whether they are similarly pronounced in populations with metabolic syndrome or diabetes.

Long-term controlled studies with clearly defined metabolic endpoints (e.g., insulin resistance, HbA1c) and differentiation of the effects of individual polyphenols such as hydroxytyrosol in various patient groups are still pending.

Bone and Joints

In a double-blind, randomised, placebo-controlled study involving 64 postmenopausal women with osteopenia (lumbar spine T-score -1.5 to -2.5), the effect of an olive polyphenol extract (250 mg/day) combined with 1000 mg calcium was investigated over 12 months. The primary endpoint was changes in bone turnover markers, with secondary endpoints including bone mineral density (BMD) and lipid profile. Compared to placebo (calcium only), the osteoblastic marker protein osteocalcin increased significantly in serum (p < 0.05), while BMD remained stable. The lipid profile also improved (reduction in LDL cholesterol, p < 0.05). The study showed a positive effect on bone metabolism for the combination, though data on fracture rates and the specific effects of hydroxytyrosol or other individual polyphenols within the extract are lacking 5.

Hypothesis The observed increase in osteocalcin suggests that olive polyphenols such as oleuropein and hydroxytyrosol promote osteoblast activity and may potentially counteract bone loss. However, it remains unclear whether these effects are sufficient to influence clinically relevant endpoints such as fractures or whether they are primarily due to antioxidant or hormonal mechanisms.

Long-term studies with hard endpoints (fracture rates) and larger sample sizes are lacking to assess the clinical relevance for osteoporosis prevention.

Heart and Circulation

In a randomised crossover study involving nine healthy men, the acute effect of extra virgin olive oil with varying oleocanthal and oleacein content on platelet function was investigated. Participants received 40 ml of olive oil weekly with either low (D2i 0.5: 1:2 oleacein/oleocanthal), high (D2i 2: 2:1 oleacein/oleocanthal), or predominantly tyrosol content. Maximum platelet aggregation (Pmax) following stimulation with 1 µg/ml collagen decreased significantly after intake of oils with high oleocanthal content (D2i 0.5 and D2i 2), with the effect most strongly correlated with oleocanthal dose (R = 0.56, p = 0.002). Inhibition of eicosanoid production suggests a COX-independent mechanism. The study showed dose-dependent effects on platelet function, though data on long-term clinical outcomes and applicability to at-risk populations are lacking 7.

Hypothesis The antithrombotic effects of oleocanthal may be due to direct inhibition of platelet activation, potentially via modulation of pathways such as TRPA1 (see study 22). However, it remains unclear whether these effects are similarly pronounced in populations with cardiovascular risk factors (e.g., diabetes, hypertension) or whether they are influenced by other dietary components.

Controlled human studies with cardiovascular endpoints (e.g., myocardial infarction, stroke) and longer intervention durations are part of the research landscape, but represent a smaller subset of the available evidence on olive polyphenols.

Gut and Microbiome

In a randomised, controlled, blinded crossover study involving 12 healthy participants, the bioavailability and metabolism of hydroxytyrosol from two olive-based dietary supplements (30.58 mg and 61.48 mg hydroxytyrosol per dose, respectively) were investigated in comparison to hydroxytyrosol-enriched olive oil. Primary endpoints were plasma concentrations and urinary excretion of hydroxytyrosol and its metabolites (homovanillic acid, hydroxytyrosol-3-O-sulphate, DOPAC). Bioavailability increased in a dose-dependent manner, with the highest concentrations of metabolites measured after 1–2 hours in plasma and after 12 hours in urine. The study showed that hydroxytyrosol from dietary supplements is bioavailable; however, data on modulation of the gut microbiota and long-term effects are lacking 10.

Hypothesis The bioavailability of hydroxytyrosol may be influenced by the gut microbiota, as part of its metabolism occurs in the gut. However, it remains unclear whether polyphenols, like hydroxytyrosol, directly alter the composition of the microbiota or primarily act via systemic effects (e.g., anti-inflammatory mechanisms).

Oxidative Stress

In a randomised, double-blind, placebo-controlled study involving 80 children with non-alcoholic fatty liver disease (NAFLD), the effects of a combination of hydroxytyrosol (HXT) and vitamin E were investigated over four months. Primary endpoints included oxidative stress parameters (e.g., advanced glycation end products, carbonylated proteins) and liver ultrasound. The combination treatment led to a significant improvement in oxidative stress markers and a reduction in steatosis, with the improvement in steatosis correlating with the reduction in oxidative stress parameters (p < 0.05). The study showed the antioxidant effects of the combination therapy; however, the specific contribution of hydroxytyrosol alone remains unclear, and data on its long-term effects are lacking 13.

Hypothesis The antioxidant effects of hydroxytyrosol may be attributed to its direct radical-scavenging function as well as the induction of endogenous antioxidant enzymes (e.g., catalase, superoxide dismutase) (see study 12). However, it remains unclear whether these effects are similarly pronounced in populations with chronic diseases (e.g., diabetes, cardiovascular diseases).

Controlled human studies on the dose-dependent effects of hydroxytyrosol on oxidative stress markers in different populations are limited, as are long-term investigations of its impact on clinical endpoints (e.g., progression of NAFLD).

Overall Picture

The available studies show that hydroxytyrosol from olive leaves and oils exhibits multiple health-promoting effects. Its anti-inflammatory, antioxidant, and cardioprotective properties are particularly investigated, mediated through the modulation of cytokines (IL-6, IL-8, IFN-γ), improvement of endothelial function, and reduction of oxidative stress. The bioavailability of hydroxytyrosol is dose- and matrix-dependent, with native oils and liquid extracts enhancing absorption. Additionally, preliminary data indicate positive effects on bone metabolism, glucose metabolism, and gut health.

Despite these promising results, the evidence remains limited in certain areas. In particular, there is a lack of long-term studies with clinically relevant endpoints (e.g., fracture rates, cardiovascular events, progression of NAFLD) and systematic dose-response analyses. Most studies have been conducted in healthy participants or small patient groups, leaving the applicability to high-risk populations (e.g., elderly patients, those with metabolic syndrome) uncertain. Furthermore, the preparations (extracts vs. native oils) and dosages used vary widely, complicating direct comparisons.

3. How Robust the Research Is

The evaluated publications are unevenly distributed between basic research and human studies, with the latter predominantly observational in design. Controlled human studies focus mainly on metabolic parameters, cardiovascular markers, and antioxidant/anti-inflammatory effects. Far less frequently investigated are gut health, immune modulation, or antiviral effects. The most cited controlled studies primarily examine insulin resistance, blood pressure, vascular function, and bone markers, while clinical endpoints (e.g., disease progression) are rarely addressed. A notable discrepancy exists between laboratory and human research: while antiproliferative, neuroprotective, and antimicrobial effects are described in vitro and in animal models, these findings remain preclinical, and controlled human studies for these applications are almost entirely lacking.

The methodological robustness of human studies is inconsistent. Strengths of the field include randomised, placebo-controlled designs in the most cited studies and the measurement of surrogate parameters (e.g., LDL oxidation, inflammatory markers) using standardised methods. Weaknesses include small sample sizes, short intervention periods, and heterogeneous formulations. Many studies use enriched extracts whose polyphenol profiles are not always fully characterised. Additionally, dose-finding studies are often absent, leaving it unclear whether observed effects are physiologically relevant. While review articles highlight potential mechanisms (e.g., NF-κB inhibition, microbiome modulation), their applicability to humans remains speculative. Particularly critical: long-term data on safety and efficacy are lacking, and interactions with medications (e.g., antihypertensives) are scarcely investigated.

4. Common Claims and the Supporting Evidence

5. The Most Robust Studies

Ranked by strength of evidence, not by prominence. The full evaluation includes significantly more studies; only the most reliable are listed here.

Controlled Human Studies

• 1 Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomised, placebo-controlled, crossover trial (2013)
• 2 Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract (2013)
• 3 Oleuropein, a bioactive compound from Olea europaea L., as a potential preventive and therapeutic agent in non-communicable diseases (2019)
• 4 Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril (2011)
• 5 Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double-blind, randomised trial increases serum total osteocalcin levels (2015)
• 6 Secoiridoids delivered as olive leaf extract induce acute improvements in human vascular function and reduction of an inflammatory cytokine: a randomised trial (2015)
• 7 Oleocanthal-rich extra virgin olive oil demonstrates acute anti-platelet effects in healthy men in a randomised trial (2017)
• 8 Pharmacokinetics and bioavailability of hydroxytyrosol are dependent on the food matrix in humans (2021)
• 9 Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans: a randomised, controlled trial (2019)
• 10 Oral bioavailability and metabolism of hydroxytyrosol from food supplements (2023)
• **** Anti-inflammatory effect of white wine in CKD patients and healthy volunteers (2015)
• 11 Effects of olive oil and its components on intestinal inflammation and inflammatory bowel disease (2022)
• 12 Effects of postprandial hydroxytyrosol and derivatives on LDL oxidation, cardiometabolic state and gene expression: a nutrigenomic approach for cardiovascular prevention (2019)
• 13 The antioxidant effects of hydroxytyrosol and vitamin E on paediatric non-alcoholic fatty liver disease: a clinical trial—a new treatment? (2019)
• **** The effects of an olive fruit polyphenol-enriched yoghurt on body composition, blood redox status, physiological and metabolic parameters and yoghurt microbiology (2016)
• 14 Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes: the APRIL study (2023)
• 15 Supplementation effect of a combination of olive (Olea europaea L.) leaf and fruit extracts in the clinical management of hypertension and metabolic syndrome: a randomised trial (2020)
• 16 The effect of olive leaf extract in decreasing the expression of two pro-inflammatory cytokines in patients receiving chemotherapy for cancer: a randomised trial (2013)
• 17 The effect of dietary intervention with high-oleocanthal and oleacein olive oil in patients with early-stage chronic lymphocytic leukaemia: a pilot randomised trial (2021)
• **** A randomised study of nutritional supplementation in patients with unilateral wet age-related macular degeneration (2021)
• 18 Systemic health effects of oleuropein and hydroxytyrosol supplementation: a systematic review of randomised controlled trials (2024)
• 19 Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q₁₀ on lipid levels: a randomised, double-blind, placebo-controlled trial (2017)
• 20 The effect of olive leaf extract on cardiovascular health markers: a randomised placebo-controlled clinical trial (2021)
• 21 Effect of a combination of citrus flavones and flavanones and olive polyphenols for the reduction of cardiovascular disease risk: an exploratory randomised trial (2020)

6. Summary

What is evidenced: Polyphenols such as hydroxytyrosol and oleuropein demonstrate effects on metabolic and cardiovascular parameters in controlled human studies. These include reductions in blood pressure, improvements in insulin sensitivity, modulation of inflammatory markers (IL-6, IL-8, IFN-γ), and enhancement of endothelial function. Bioavailability is highly dependent on the form of administration, with native olive oil favouring absorption. Additionally, there is evidence of positive effects on bone metabolism (e.g., increased osteocalcin). However, most studies assess surrogate parameters rather than clinical endpoints such as disease progression or fracture rates.

Hypothesis The observed effects may stem from multiple mechanisms, including antioxidant properties, inhibition of NF-κB, or modulation of the microbiome. However, it remains unclear whether the effects are primarily attributable to hydroxytyrosol or other polyphenols such as oleuropein, as studies often use mixtures. The endogenous conversion of tyrosol to hydroxytyrosol could amplify cardioprotective effects, but dose-finding studies are lacking to define physiologically relevant amounts. The discrepancy between laboratory and human research suggests that some in vitro effects (e.g., neuroprotective) may not be transferable to humans.

What a study would need to clarify: Large-scale, multicentre long-term studies with clearly defined dose-response relationships and differentiation of individual polyphenols are necessary to validate the clinical relevance for chronic inflammatory diseases, metabolic syndrome, or osteoporosis. Additionally, systematic investigations into bioavailability in complex meals and across different populations (e.g., elderly patients, those with malabsorption) should be conducted. Studies on interactions with medications and long-term safety, particularly for high-dose extracts, are also important. Finally, studies directly measuring clinical endpoints (e.g., cardiovascular events, fracture rates) are lacking to assess the transferability of surrogate parameters.

7. Broader Context

Evidence-based: Olive polyphenols, particularly hydroxytyrosol, demonstrate measurable effects on key metabolic and cardiovascular parameters in controlled human studies. Evidence includes improvements in vascular function (e.g., endothelium-dependent vasodilation), reductions in systolic blood pressure, and positive influences on insulin resistance and lipid profiles. These findings correlate with the substance’s high antioxidant capacity, which in vivo is primarily mediated via metabolites such as sulphate and glucuronide conjugates. The data are largely derived from short-term interventional studies using standardised extracts or native olive oil, while long-term effects or clinical endpoints (e.g., cardiovascular events) remain scarcely documented. A critical consideration is transferability: bioavailability varies significantly depending on the form of administration (aqueous vs. fat-soluble), and the observed effects are often dose-dependent but not linear. Nonetheless, these findings position hydroxytyrosol as a relevant modulator in the oxidative stress regulation cascade—particularly in interplay with endogenous systems such as Nrf2 or glutathione, the activation of which has been demonstrated in vitro.

Plausible The mechanistic plausibility of hydroxytyrosol’s effects arises from its chemical structure and the actions observed in animal models and in vitro studies. As a secoiridoid with a phenolic hydroxyl group, it acts as a direct radical scavenger but also stabilises reactive oxygen species through chelation with transition metals. In the context of mitochondrial function, it exhibits a dual role: on the one hand, hydroxytyrosol protects against oxidative damage to mitochondrial DNA and membranes; on the other, it modulates the electron transport chain, which may lead to more efficient ATP synthesis. These effects are closely linked to the activation of the Nrf2 signalling pathway, which upregulates the expression of antioxidant enzymes such as SOD or glutathione peroxidase. Additionally, preclinical data suggest an interaction with the gut barrier: hydroxytyrosol promotes the proliferation of butyrate-producing bacteria (e.g., Faecalibacterium prausnitzii) and reduces pro-inflammatory cytokines in the gut milieu. Here, its profile overlaps with that of zeolite, which also shares microbiome modulation as a common denominator—though studies investigating these substances in combination are lacking. The plausibility of these mechanisms is further supported by the structural similarity to other olive polyphenols such as oleocanthal, which additionally mediates anti-inflammatory effects via inhibition of COX enzymes.

Hypothesis The available data suggest that hydroxytyrosol may exert its strongest systemic effects where oxidative stress regulation, mitochondrial function, and gut barrier integrity converge. A central, yet untested, hypothesis is that the substance—similar to butyrate—influences the gut-brain or gut-liver axis by modulating the production of short-chain fatty acids while simultaneously reducing intestinal permeability. This could explain why neuroprotective effects are observed in animal models, whereas human studies are lacking. Particularly worth investigating is whether hydroxytyrosol, in combination with other barrier-nourishing substances (e.g., L-glutamine) or microbiome-modulating agents (e.g., probiotics), demonstrates synergistic effects on inflammatory markers or metabolic parameters. Another unresolved question is whether the antiviral activity observed in vitro (e.g., against influenza viruses) stems from direct interaction with viral proteins or from strengthening mucosal immunity—and whether this is clinically relevant. Methodologically, controlled studies using standardised extracts and clearly defined biomarkers (e.g., zonulin for gut barrier integrity, mtDNA damage for mitochondrial function) would be required to validate the transferability of preclinical findings.

8. Open Questions

• Dose-response relationship: Unclear whether observed effects occur at physiological concentrations (e.g., through diet) or only with high-dose extracts within the studied dosage ranges.
• Long-term safety: No studies exceeding 12 months in duration exist, leaving risks of prolonged use unknown.
• Interactions: Potential interactions with medications (e.g., antihypertensives, anticoagulants) have not been systematically investigated.

9. Further Paths

Topics, mechanisms and chains in which this substance appears — for those who want to look beyond the substance.

• Gut barrier and binding: polyphenols, zeolite, butyrate, probiotics
• Oxidative stress, mitochondria, and energy